AR124749A1 - Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades - Google Patents
Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedadesInfo
- Publication number
- AR124749A1 AR124749A1 ARP200100485A ARP200100485A AR124749A1 AR 124749 A1 AR124749 A1 AR 124749A1 AR P200100485 A ARP200100485 A AR P200100485A AR P200100485 A ARP200100485 A AR P200100485A AR 124749 A1 AR124749 A1 AR 124749A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- optionally substituted
- alkyl optionally
- alkyl
- membered monocyclic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 208000019180 nutritional disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1902490.0A GB201902490D0 (en) | 2019-02-25 | 2019-02-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124749A1 true AR124749A1 (es) | 2023-05-03 |
Family
ID=65998935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100485A AR124749A1 (es) | 2019-02-25 | 2020-02-21 | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220144823A1 (https=) |
| EP (1) | EP3931191B1 (https=) |
| JP (1) | JP2022525121A (https=) |
| KR (1) | KR20210134001A (https=) |
| CN (1) | CN113474344A (https=) |
| AR (1) | AR124749A1 (https=) |
| AU (1) | AU2020229041A1 (https=) |
| BR (1) | BR112021016642A2 (https=) |
| CA (1) | CA3130154A1 (https=) |
| CO (1) | CO2021010485A2 (https=) |
| ES (1) | ES2963409T3 (https=) |
| GB (1) | GB201902490D0 (https=) |
| IL (1) | IL285751A (https=) |
| MA (1) | MA55074A (https=) |
| MX (1) | MX2021010093A (https=) |
| PH (1) | PH12021552032A1 (https=) |
| SG (1) | SG11202109157TA (https=) |
| TW (1) | TW202045505A (https=) |
| WO (1) | WO2020173739A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022070288A1 (ja) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | 含窒素二環化合物 |
| WO2025143152A1 (ja) * | 2023-12-27 | 2025-07-03 | 全薬工業株式会社 | チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| JP2011530511A (ja) * | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| WO2010090716A1 (en) * | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US10392389B2 (en) * | 2012-10-25 | 2019-08-27 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of PASK |
| CA2969265A1 (en) * | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
| EP3615538B1 (en) * | 2017-04-27 | 2024-02-07 | The Brigham and Women's Hospital, Inc. | Novel alk2 inhibitors and methods for inhibiting bmp signaling |
-
2019
- 2019-02-25 GB GBGB1902490.0A patent/GB201902490D0/en not_active Ceased
-
2020
- 2020-02-17 AU AU2020229041A patent/AU2020229041A1/en not_active Abandoned
- 2020-02-17 SG SG11202109157TA patent/SG11202109157TA/en unknown
- 2020-02-17 ES ES20706194T patent/ES2963409T3/es active Active
- 2020-02-17 WO PCT/EP2020/054122 patent/WO2020173739A1/en not_active Ceased
- 2020-02-17 EP EP20706194.6A patent/EP3931191B1/en active Active
- 2020-02-17 CA CA3130154A patent/CA3130154A1/en active Pending
- 2020-02-17 US US17/433,503 patent/US20220144823A1/en not_active Abandoned
- 2020-02-17 BR BR112021016642A patent/BR112021016642A2/pt not_active IP Right Cessation
- 2020-02-17 MX MX2021010093A patent/MX2021010093A/es unknown
- 2020-02-17 PH PH1/2021/552032A patent/PH12021552032A1/en unknown
- 2020-02-17 CN CN202080016700.3A patent/CN113474344A/zh active Pending
- 2020-02-17 MA MA055074A patent/MA55074A/fr unknown
- 2020-02-17 JP JP2021555034A patent/JP2022525121A/ja active Pending
- 2020-02-17 KR KR1020217030814A patent/KR20210134001A/ko not_active Ceased
- 2020-02-21 AR ARP200100485A patent/AR124749A1/es not_active Application Discontinuation
- 2020-02-24 TW TW109105861A patent/TW202045505A/zh unknown
-
2021
- 2021-08-10 CO CONC2021/0010485A patent/CO2021010485A2/es unknown
- 2021-08-22 IL IL285751A patent/IL285751A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3130154A1 (en) | 2020-09-03 |
| TW202045505A (zh) | 2020-12-16 |
| SG11202109157TA (en) | 2021-09-29 |
| MA55074A (fr) | 2022-01-05 |
| ES2963409T3 (es) | 2024-03-27 |
| MX2021010093A (es) | 2021-09-21 |
| BR112021016642A2 (pt) | 2021-11-03 |
| KR20210134001A (ko) | 2021-11-08 |
| IL285751A (en) | 2021-10-31 |
| US20220144823A1 (en) | 2022-05-12 |
| PH12021552032A1 (en) | 2022-11-14 |
| AU2020229041A1 (en) | 2021-10-21 |
| WO2020173739A1 (en) | 2020-09-03 |
| EP3931191A1 (en) | 2022-01-05 |
| GB201902490D0 (en) | 2019-04-10 |
| CN113474344A (zh) | 2021-10-01 |
| JP2022525121A (ja) | 2022-05-11 |
| EP3931191B1 (en) | 2023-10-04 |
| CO2021010485A2 (es) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104362A1 (es) | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| AR097862A1 (es) | Inhibidores de tirosina quinasa de bruton | |
| MX2019000123A (es) | Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores. | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| AR104880A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
| AR108906A1 (es) | Heterociclos de biarilmetilo | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR118521A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |